Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of myeloma. By exploiting the inherent high immunoglobulin protein production of malignant plasma cells, bortezomib induces endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), resulting in myeloma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Wallington-Beddoe, Craig T., Bennett, Melissa K., Vandyke, Kate, Davies, Lorena, Zebol, Julia R., Moretti, Paul A.B., Pitman, Melissa R., Hewett, Duncan R., Zannettino, Andrew C.W., Pitson, Stuart M
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Priority Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546428/
https://ncbi.nlm.nih.gov/pubmed/28467788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17115
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars